All In Biotech

NDA 021710 · Validus Pharms

Equetro

Carbamazepine · Oral · Mood Stabilizer

Last checked: Nov 20, 2026Latest source record: Oct 14, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

Dec 10, 2004

Approved uses

3

Original approval plus efficacy supplements

Registered trials

199

31 Phase 3, 6 recruiting

FAERS reports

36,992

32,657 serious, 3,861 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING:SERIOUS DERMATOLOGIC REACTIONS AND APLASTIC ANEMIA AND AGRANULOCYTOSIS Serious Dermatologic Reactions and HLA-B*1502 Allele Serious and sometimes fatal dermatologic reactions, including toxic epidermal necrolysis (TEN) and Stevens-Johnson Syndrome (SJS), have occurredb in patients treated with carbamazepine. These syndromes may be accompanied by mucous membrane ulcers, fever, or painful rash. These reactions are estimated to occur in 1 to 6 per 10,000 new users in countries with mainly Caucasian populations, but the risk in patients of Asian descent is estimated to be about 10 times higher. There is a strong association between the risk of developing SJS/TEN and the presence of HLA-B*1502, an inherited allelic variant of the HLA-B gene. Test for HLA-B*1502, prior to initiating EQUETROin patients with an increased likelihood of carrying this allele. Avoid use of EQUETRO in...

What it is approved for

From the label in effect Aug 19, 2025.

EQUETRO is: A mood stabilizer indicated for the treatment of acute manic or mixed episodes associated with bipolar I disorder ( 1.1 ) Indicated for the treatment of the pain associated with trigeminal neuralgia ( 1.2 ) An anti-epileptic drug (AED) indicated for the treatment of partial seizures with complex symptomatology, generalized tonic-clonic seizures, and mixed seizures ( 1.3 ) 1.1Acute Manic or Mixed Episodes associated with Bipolar I Disorder EQUETRO is indicated for treatment of patients with acute manic or mixed episodes associated with bipolar I disorder [see Clinical Studies ( 14.1 ) ] . 1.2 Pain of Trigeminal Neuralgia EQUETRO is indicated in the treatment of the pain associated with trigeminal neuralgia. Beneficial results have also been reported in glossopharyngeal neuralgia. This drug is not a simple analgesic and should not be used for the relief of trivial aches or pains. 1.3 Epilepsy EQUETRO is indicated for the treatment of partial seizures with complex symptomatology (e.g., psychomotor, temporal lobe), generalized tonic-clonic seizures (grand mal), and mixed seizure patterns, which include the seizure types listed here or other partial or generalized seizures. Limitations of Usage EQUETRO is not indicated for the treatment of absence seizures (petit mal).Carbamazepine has been associated with increased frequency of generalized convulsions in these patients.

Mechanism: 1 2 .1 Mechanism of Action The mechanism of action of carbamazepine in the treatment of acute manic or mixed episodes associated with bipolar disorder is unclear.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • EQUETRO · CARBAMAZEPINE 300MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
  • EQUETRO · CARBAMAZEPINE 100MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
  • EQUETRO · CARBAMAZEPINE 200MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Carbamazepine" as an intervention, any sponsor and status, largest first.

All 199 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective3,567
  • drug interaction2,501
  • toxicity to various agents2,361
  • seizure2,013
  • off label use1,899
  • fall1,863
  • dizziness1,527
  • pain1,412
  • fatigue1,399
  • pyrexia1,388
  • condition aggravated1,276
  • somnolence1,251

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004607
2005772
2006773
2007684
2008900
20091,035
2010965
20111,195
20121,379
20131,125
20141,268
20151,654
20161,857
20172,003
20182,765
20192,592
20202,185
20212,606
20222,402
20232,114
20242,086
20252,216
20261,803

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Equetro (Carbamazepine)

2024 spending

$1.0M

Beneficiaries

397

2,532 claims

Per beneficiary

$2,637

$4.39 per unit

View as table
YearSpending
2020$1,983,989
2021$1,519,402
2022$1,368,531
2023$1,205,614
2024$1,047,004

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,597 on PubMed

Sponsor: Validus Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.